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BriefDefinitive Report
IL-2 alone or in combination with the adoptive transfer of either lymphocyte-
activated killer cells(LAK)or tumor-infiltrating lymphocytes(TIL)hasshownefficacy
in the treatment of certain human malignancies (1, 2) . However, IL-2-based im-
munotherapy protocolsare associated with considerable systemic toxicity (1, 3) . The
pathophysiologic consequences of high dose IL-2 administration in man are vari-
ably composed of a "vascular leak syndrome, marked fluid retention and weight
gain, decreased systemic vascular resistance, increased cardiac output, hypotension,
elevated creatinine, and elevated bilirubin (4-7) . This constellation of changes is
remarkably similar to the alterations seen in septic shock.A series of recent investi-
gations have identified the monocyte/macrophage product, TNF, as an important
mediator of toxicity in endotoxemia and Gram-negative sepsis (8, 9) . The clinical
similarities between IL-2 toxicity and sepsis suggest a potential role forTNF as a
mediator of the toxic effects of IL-2 (3) . Evidence to support this hypothesis is that
IL-2 induces transcription and translation ofTNF inLAK cells and macrophages
(10-12), as well as recent studies thatmeasure circulatingTNF in humans receiving
IL-2 alone or IL-2 and LAK (13, 14) .
The present study investigates the role ofTNF in IL-2 toxicity by administering
high levels ofneutralizing antiTNF antibody concurrently with high dose IL-2 treat-
ment in mice. The effects ofTNFantibody on IL-2 toxicity as well as the antitumor
efficacy of IL-2 are evaluated .
Materials and Methods
Mice.
￿
Female C57BL/6mice andC3H/HENmice 12-16wk oldwere obtained from the
small animals section, Veterinary Resources Branch, NIH, Bethesda, MD.
muTNFAntibodyPrefiaration.
￿
New Zealand white rabbits3-4kgwere immunized to recom-
binant murine TNF=a(rmuTNF) (Genentech, South San Francisco, CA) or to recombinant
rat IFN-y (Amgen Corp ., Thousand Oaks, CA) and bled in a standard fashion . Sera were
passed over arecombinantproteinAcolumn (10ml bedvolume), washed, eluted, and desalted
permanufacturer's recommendations(Beckman Instruments, Inc., Fullerton, CA). Column
aliquots were screened forTNF antibody as describedbelowand positive aliquots were pooled
to obtain the TNF antibody solution used in all experiments.
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Characterization ofrmuTNFAntibody .
￿
Theneutralizing activity of the TNF antibody solution
was quantitated by serial dilution using the L929 cytolytic assay (15). The greatest dilution
ofantibody solution that led to100% survival ofL929 cellswasused toquantitate neutralizing
activity . IgG concentration ofthe antibody solution wasmeasured by radial immunodiffusion
(ICN Immunobiologicals, Irvine, CA) .
Pulmonary Metastases TumorModel.
￿
A murine pulmonary metastases model using a weakly
immunogenic methylcholanthrene-induced tumor(MCA-106) wasused . Tumorpreparation
and analysis were done as previously described (16) ; metastases were counted in a blinded
fashion (17). By prior convention, iftherewere >250 metastases that lung was scored as >250
as higher numbers oflesions could notbe counted (17) . Mice were treated with recombinant
human IL-2 (Cetus Corp., Emeryville, CA) 100,000 U i.p. every 8 h or HBSS control .
Statistics .
￿
Survival curves were analyzed by theBreslow modification ofthe KruskalWallis
test . Metastases number are shown as mean t SEM and compared by the Wilcoxon Rank
Sum test corrected for multiple comparisons .
Results and Discussion
The polyvalent antisera to recombinant murine TNF used in allexperiments neu-
tralized 5 x 106U of TNF per milliliter of antibody solution in a standard L929
cytolytic assay . The specificity of the antisera was evaluated by bioassay and immu-
noblot techniques. The TNF antibody had no neutralizing activity against HL-2
in aCTLL proliferation assay(datanot shown). To evaluate the efficacy of theTNF
establish an appropriate in vi
theexperiment ofBeutler et al . (8) usingpolyvalentTNFantibody to protect against
alethal dose of endotoxin . Pretreatment of mice with 5 x 10 5 U i.p . of neutralizing
activity 6h before challenge with an LDloo dose of endotoxin gave complete pro-
tection from death in all mice ; whereas pretreatment with 2.5 x 105 U of neu-
tralizing activity afforded no protection.
To determine the effects of TNF antibody on IL-2 toxicity, mice were injected
with 100,000Ui.p. ofIL-2 every 8 h andthe number of doses ofIL-2 received before
death was recorded . C3H/HEN mice receiving control rabbit IgG died reprodu-
cibly after receiving 10-12 doses of IL-2 (mean dose, 11.1) . Mice that were injected
with varying doses ofTNF antibody ranging from 0.5 to 2.0 x 106 U i.p . of neu-
tralizing activity once dailyduring IL-2 treatment survived significantlymore doses
of IL-2 than control mice treated with nonspecific antibody (p < 0.005 vs . control
for allTNF antibody groups; Fig. I A) . Theprotective effect ofTNFantibody against
IL-2 lethality was observed as a dose-response . Another control using polyvalent
rabbit antisera against rat IFN was no different than control rabbit IgG, indicating
that theTNF protective effect was notdue to administration of a hyperimmune sera
(Fig. 1 A) .
TNFantibody afforded a similar protective effect against IL-2 toxicity in C57BL/6
mice with microscopic (3 day) andmacroscopic (10day) pulmonarysarcomametastases
(Fig . 1 B) . The mean dose of IL-2 plus control IgG that resulted in death was 14.5
for mice with 3-d pulmonary metastases and 14 for mice with 10-d pulmonary
metastases, but 14/15 mice with 3-d pulmonary metastases and 12/12 mice with 10-d
metastases treated with antibody to TNF tolerated 20 doses of IL-2 without mor-
tality (ß < 0.001).
The effect ofTNF antibody on the antitumor activity of IL-2 can be evaluated
by comparing the treatment response of mice receiving equal doses of IL-2 with
or without theTNF antibody. Mice given IL-2 withTNFantibody have significantlyFRAKER ET AL .
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FIGURE 1 .
￿
Survival curves for mice
receiving IL-2 and TNF antibody or
"'
￿
control antibody. (A) Non-tumor-
bearingC3HIHEN micewereinjected
with 100,000 U i.p . of IL-2 in 0.5 ml
HBSS every 8 h and the number of
doses until death was recorded . Mice
received daily injections of0.4 ml of
4011
￿
either control rabbit IgG, varying
quantities of anti-murine TNF anti-
bodies, or anti rat IFN-y antibodies .
Control rabbit IgG(* ; n = 14); 0.5 x
to
￿
is
￿
2a
￿
106 neutralizing units TNF Ab once
daily (O ; n = 6) ; 1.25 x 106 neu-
tralizing units TNF Ab (0 ; n = 6) ;
2.0 x 106 neutralizing units TNF Ab (0 ; n = 4) ; anti rat IFN-1' Ab (A ; n = 6). p < 0.005 for all
TNFAb groups vs . control Ab or IFN-y Ab . p < 0.05 for 1.25 x 106 or 2.0 x 106 UTNF Ab vs . 0.5
x 106 UTNFAb. (B)C57BLI6 mice were injected via tail vein with either 3 x 10 5 or 1 x 106 MCA-
106sarcoma cellsand 3-10d later treatment with 100,00UIL-2 in 0.5 ml HBSS intraperitoneally every
8 h was initiated . Mice received once daily intraperitoneal injections of either control rabbit IgG or
2 x 106 neutralizing units ofTNF Ab and survival was followed . 3-d Metastases, control Ab (* ; n
= 12); 3-d metastases,TNFAb (O ; n = 12); 10-d metastases, control Ab (N ; n = 12) ; 10-d metastases,
TNF Ab (0 ; n = 15) . p < 0.001 for TNF Ab vs . control Ab.
fewer metastases than control mice receiving the vehicle (HBSS) alone or HBSS
and TNF antibody (p< 0 .001 vs . both HBSS controls in all experiments ; Table I) .
TNF antibody-treated mice have aconsistent but not statistically significant increase
in pulmonary metastases compared with mice receiving an equal amount of IL-2
with control antibody in three experiments .
Whether additional administration of IL-2 made possible by the protective effect
ofTNF antibody improves the therapeutic response can be evaluatedbycomps
mice receiving equitoxic amounts of IL-2 with or without the TNF antibody . The
maximal amount of IL-2 tolerated by mice receiving control antibody was given
in the experiments shown in Table I, as evidenced by the occurrence of IL-2 treat-
ment deaths . One subgroup of mice givenTNF antibody received additional IL-2
until obvious toxicity and imminent mortality was observed, and these mice can
be considered to have received equitoxic doses of IL-2 compared with mice given
control antibody and IL-2 . In the 3-d pulmonary metastases model, IL-2 alone is
so effective, 96 and 89% reduction in metastases number in Exps . I and 2, respec-
tively (Table I), that it is difficult to demonstrate an improved therapeutic effect with
additional doses of IL-2 made possible by TNF antibody in this micrometastases
model .
In mice given 3 x 106 MCA-106 cells and treated at 10 d after tumor injection
with 20 doses ofIL-2 plus TNF antibody (Exp . 3) there was a modest but insignificant
decrease in pulmonary metastases compared with mice given 12 doses of IL-2 and
control antibody (24 vs. 53 metastases, ib = 0.06 ; Table I) . In a similar 10-d metastases
experiment in which mice were injected with 106 MCA-106, an improved response
after additional IL-2 administration was more apparent . In this experiment control
mice given HBSS with control or TNF antibody had >250 metastases (Fig . 2, A
and B) . Mice given 12 doses of IL-2 and daily control antibody had an IL-2 treat-
ment mortality of 25% (3112) and the remaining nine micehad a mean of 230 pul-
monary metastases (Fig . 2 G") . Again, mice given an equal number of doses of IL-2101 8
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TABLE I
Effect of IL-2 and TNF Antibody on Microscopic (3-d) and
Macroscopic (10-d) Pulmonary Metastases
Exp . 1 is the treatment of 3-d pulmonary metastases after intravenous injection of 3 x 105
MCA-106 cells . Exp . 2 is the treatment of3-d pulmonary metastases after intravenous injec-
tion of 106 MCA-106 cells . Exp . 3 is the treatment of 10-d pulmonary metastases after in-
travenous injection of 3 x 105 MCA-106 cells .
Treatment consisted of 100,000 U i.p . ofIL-2 every 8 h in 0 .5 ml HBSS or HBSS alone .
TNF antibody (Ab)-treated mice received 2 x 106U i.p. of Ab once daily or the equivalent
rabbit IgG control . Treatment with both agents was begun 3 d or 10 d after MCA-106 tumor
cell injection . Number of metastases are shown as mean t SEM . Tx, treatment .
* p < 0.001 vs . HBSS groups .
with TNF antibody had asimilar IL-2 treatment reponse (meannumber of metastases,
228 ; Fig. 2D) . A second subgroup ofmice given dailyTNF antibody in this experi-
ment tolerated 20 dosesof IL-2 without treatment mortality and thenumber of meta-
tases was 173 (p < 0.02 vs . IL-2 plus control antibody) . Although the apparent de-
FIGURE 2 . Lungs from mice
injected with 1 x 106 MCA-106
cells 10 d before treatment with
thrice daily injection of HBSS
or 100,000U of IL-2 intraperi-
toneally and daily injections of
rabbit IgG or 2 x 10 6 U neu-
tralizing activity ofTNF anti-
body. Lungs were treated with
India ink and Fekete's such that
tumor metastases appear white
on a black background of nor-
mal lung. (A) HBSS and con-
trol rabbit IgG; (B) HBSS and
TNF antibody ; (C) 12 doses of
IL-2 and controlrabbit IgG; (D)
12 doses ofIL-2 andTNF anti-
body ; (E) 20 doses of IL-2 and
TNF antibody .
Exp . n TNF Ab Tx
No . of
IL-2 doses
IL-2
tx deaths
No . of
metastases
1 12 - HBSS - - 168 1 17
6 + HBSS - - 167 1 12
12 - IL-2 12 3/12 (25%) 7 t 4*
6 + IL-2 12 0/6 (0%) 32 t 14*
6 + IL-2 20 0/6 (0%) 5 t 2*
2 12 - HBSS - - >250
6 + HBSS - - >250
24 - IL-2 14 5/24 (21%) 28 t 8*
6 + IL-2 14 0/6 (0%) 47 ± 14*
9 + IL-2 20 1/9 (11%) 23 t 6*
3 12 - HBSS - - 171 t 15
6 + HBSS - - 173 1 24
24 - IL-2 12 2/24 (8%) 53 t 8*
6 + IL-2 12 0/6 (0%) 83 t 9*
6 + IL-2 21 0/6 (0%) 24 t 8*FRAKER ET AL.
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crease in tumor number is relatively small, the actual decrease in tumor burden
by the additional eight doses of IL-2 made possible by concurrent TNF antibody
is greater as the size of the metastases in this group also appears to be substantially
decreased (Fig. 2 E).
The resultsin both non-tumor-bearing andtumor-bearing mice indicate that en-
dogenous TNFproduction is amediator ofsystemic IL-2 toxicity. Mice treatedwith
TNF antibody tolerate between 30 and 60% more IL-2 than control mice before
IL-2 death. SinceTNF antibody-treated mice eventually die secondary to IL-2 tox-
icity despite continued antibody injection, then either other mechanisms of IL-2
toxicity exist or inadequate amounts of TNF antibody were given. The former ex-
planationis most likely. IL-2 administration inducesotherpotentially toxichost factors
such as lymphotoxin, IFN-y, and IL-1 (10, 11, 17), as well as having pleotropic im-
mune effects that would be unaffected by TNF antibody.
Passive immunization against TNF may dissociate the toxic effects of IL-2 from
the antineoplastic activity of IL-2 . In consecutive experiments where equal doses
of IL-2 were given, the addition ofTNF antibody did not significantly alter the an-
tineoplastic effect ofIL-2. LesseningIL-2 toxicity while maintainingtreatment efficacy
is a potentially clinically relevant observation. In one experiment additional IL-2
administration made possible by TNF antibody effected amodest decrease in tumor
number but a dramatic decrease in tumor burden compared with equitoxic doses
of IL-2 plus control antibody (Fig. 2). Further experiments using different tumor
histologies at different anatomic sites are necessary to delineate the utility of TNF
antisera as a strategy to improve the therapeutic index in IL-2 immunotherapy.
Summary
Passive immunization againstTNF allowed non-tumor-bearing C3H/HEN mice
andtumor-bearingC57BL/6 mice to tolerate significantly more doses of IL-2 before
death(p < 0.005 andp <0.001, respectively). The antitumoreffect of IL-2 againstboth
3-d and 10-d pulmonary metastases was maintained in mice treated concurrently
with neutralizing antibodies to TNF . In one experiment with 10-d pulmonarymeta-
stases, increased administration of IL-2 made possible by passive immunization against
TNF significantly improved the antitumor response compared to equitoxic doses
of IL-2 and control antibody. The results indicate that TNF is a mediator of IL-2
toxicity but contributes minimallyto the antitumor effects of IL-2. Strategies to in-
hibit TNF may improve the therapeutic index of IL-2 as a neoplastic agent.
Receivedforpublication 20 April 1989 and in revisedform 12 June 1989.
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